Skyline Therapeutics (Shanghai) Co.,Ltd. – Trademark Portfolio
Entity Type: 99
Skyline Therapeutics (Shanghai) Co.,Ltd. holds 1 U.S. trademark filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 42 (Computer & Scientific) — 1 filings in this category. The portfolio also extends into Class 5 (Pharmaceuticals) across 2 Nice Classification classes. Currently, 1 trademark is registered. Notable registered marks include CAPDRIVE.
Room 1, Floor 2, Building C,
No. 2727 Jinke Road, Pilot Free Trade Zone 201203 Shanghai
Showing of trademarks Trademarks
Trademark Classifications
Skyline Therapeutics (Shanghai) Co.,Ltd.'s trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Scientific and technological services; industrial analysis and research services
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Frequently Asked Questions
How many trademarks does Skyline Therapeutics (Shanghai) Co.,Ltd. have?
Skyline Therapeutics (Shanghai) Co.,Ltd. has 1 U.S. trademark filed with the USPTO. Of these, 1 registered.
What trademark classes does Skyline Therapeutics (Shanghai) Co.,Ltd. file in?
Skyline Therapeutics (Shanghai) Co.,Ltd. files trademarks across 2 Nice Classification classes. The most active classes are Class 42 (Computer & Scientific), Class 5 (Pharmaceuticals). Class 42 covers scientific and technological services; industrial analysis and research services.
What are Skyline Therapeutics (Shanghai) Co.,Ltd.'s most well-known trademarks?
Skyline Therapeutics (Shanghai) Co.,Ltd.'s registered trademark portfolio includes well-known marks such as CAPDRIVE. These are among 1 currently registered trademark in the portfolio.
What is Skyline Therapeutics (Shanghai) Co.,Ltd.'s trademark registration success rate?
Skyline Therapeutics (Shanghai) Co.,Ltd. has a 100% trademark registration rate, with 1 out of 1 resolved applications resulting in successful registration. Currently, 0 applications are pending review.